Benzene Ring Bonded Directly To Urea Nitrogen Patents (Class 514/596)
-
Publication number: 20110145970Abstract: The invention relates to novel modulators of the cold menthol receptor TRPM8, to a method for modulating the TRPM8 receptor using said modulators; to the use of the modulators for induction of cold sensation; and to objects and means produced using said modulators.Type: ApplicationFiled: August 26, 2009Publication date: June 23, 2011Applicant: BASF SEInventors: Thomas Subkowski, Claus Bollschweiler, Jens Wittenberg, Michael Krohn, Holger Zinke
-
Publication number: 20110110958Abstract: The invention provides compositions and methods for the treatment of neoplasias that are cytotoxic to neoplastic cells or that modulate JAZ expression, subcellular localization, or biological activity.Type: ApplicationFiled: September 11, 2008Publication date: May 12, 2011Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATIONInventors: Jingxin Qiu, Mingli Yang, David A. Ostrov, W. Stratford May
-
Publication number: 20110028545Abstract: The present invention relates to a process for producing concentrates of antimicrobial active ingredients, the concentrates themselves and their use for producing solid, liquid or pasty body cleaning compositions, such as in particular soaps.Type: ApplicationFiled: January 12, 2009Publication date: February 3, 2011Applicant: LANXESS DEUTSCHLAND GMBHInventors: Gerd-Friedrich Renner, Otto Exner, Rolf Matysiak, Josef Wellmann, Udo Hennen
-
Publication number: 20110021633Abstract: This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans, trans 1,3-butadienes, 1,3-disubstituted perhydrobutadienes, 1,2-disubstituted trans ethylenes and 1,2 disubstituted ethanes and disubstituted propanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Inventor: IBERT CLIFTON WELLS
-
Publication number: 20100261796Abstract: The present invention relates to use of novel compounds for the manufacture of a medicament for treatment of inflammatory bowel disease (IBD) as well as to a method for treatment of IBD, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification.Type: ApplicationFiled: April 26, 2006Publication date: October 14, 2010Applicant: Ferring B.V.Inventors: Pierre J-M Rivière, Chia-Ping Chang, Pierre Desreumaux
-
Publication number: 20100234349Abstract: This invention relates to novel pharmaceutical compositions comprising therapeutically effective combination of a positive allosteric modulator of nicotine receptors; and a cognitive enhancer selected from the group consisting of a nicotine acetylcholine receptor agonist, an acetylcholine esterase inhibitor, a positive AMPA receptor modulator, an antipsychotic drug, an antidepressant drug and an anti Parkinson drug. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for combating cognitive disorders.Type: ApplicationFiled: September 4, 2007Publication date: September 16, 2010Inventors: Gunnar M. Olsen, Dan Peters, Bjarne H. Dahl, Jeppe Kejser Christensen, Steven Charles Loechel, Daniel B. Timmermann
-
Publication number: 20100222431Abstract: Novel phenylurea compounds of formula (I): and cosmetic and pharmaceutical compositions containing same are useful for treating disorders of the sebaceous gland, e.g., acne, or have cosmetic applications.Type: ApplicationFiled: March 5, 2010Publication date: September 2, 2010Applicant: GALDERMA RESEARCH & DEVELOPMENTInventor: Thibaud PORTAL
-
SYNERGISTIC ACTIVE PREPARATIONS COMPRISING 1,2-DECANEDIOL AND FURTHER ANTIMICROBIAL ACTIVE COMPOUNDS
Publication number: 20100196504Abstract: The present invention relates to specific synergistic active antimicrobial compositions for hygiene disinfectant products like antimicrobial liquid or solid soaps, disinfectant cleansing solutions and disinfectant emulsions for the treatment of skin surface, specifically for the treatment of hand surface and/or for the treatment of technical surfaces like e.g. surgery equipment comprising a mixture comprising or consisting of a) an antimicrobial active amount of 1,2-decanediol of formula 1: and b) an antimicrobial active amount of one or more compounds selected from the group consisting of ethanol, propan-1-ol, propan-2-ol; chlorhexidine digluconate, chloroxylenol, triclosan, triclocarban, benzethonium chloride, methylbenzethonium chloride and benzalkonium chloride.Type: ApplicationFiled: May 4, 2007Publication date: August 5, 2010Applicant: SYMRISE GmbH & Co. KGInventors: Gerhard Schmaus, Ravikumar Pillai -
Publication number: 20100197735Abstract: Novel phenylurea compounds of formula (I): and cosmetic and pharmaceutical compositions containing same are useful for treating disorders of the sebaceous gland, e.g., acne, or have cosmetic applications.Type: ApplicationFiled: March 5, 2010Publication date: August 5, 2010Applicant: GALDERMA RESEARCH & DEVELOPMENTInventor: Thibaud Portal
-
Publication number: 20100167993Abstract: The present invention relates to a method for identifying a drug candidate for enhancing expression of p21ctpl/wafl in a human patient suffering from a medical condition that can be treated by enhancing expression of p21C?l/wafl. The method includes (a) providing a cell line comprising a nucleic acid sequence that comprises a p21ctpl/wafl promoter operationally ligated to a reporter domain; (b) exposing the cell line to a compound; and (c) identifying a compound that induces expression of the reporter domain. The compound that induces expression of the reporter domain is a drug candidate for treating a medical condition that can be treated by enhancing expression of p21cipl/wafl.Type: ApplicationFiled: June 5, 2008Publication date: July 1, 2010Applicant: CORNELL UNIVERSITYInventors: Rajiv R. Ratan, Brett C. Langley, Brian S. Ko
-
Publication number: 20100105777Abstract: The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of pain and disorders related thereto as well as a method for treatment of pain and disorders related thereto, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification.Type: ApplicationFiled: February 23, 2009Publication date: April 29, 2010Applicant: CARA THERAPEUTICS, INC.Inventors: Chia-Ping CHANG, Jacek STALEWSKI, Pierre J-M. RIVIERE, Kazimierz A. WISNIEWSKI, Claudio D. SCHTEINGART
-
Patent number: 7696249Abstract: The invention relates to novel specifically trifluoromethyl and halogen substituted 1,3-diphenyl ureas and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects like the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as anti-infectives.Type: GrantFiled: December 8, 2006Date of Patent: April 13, 2010Assignee: ARPIDA AGInventors: Ralf Loewe, Sergio Lociuro, Stephen Hawser, Laurent Schmitt
-
Patent number: 7678812Abstract: This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to ?-aminotetralin-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.Type: GrantFiled: October 23, 2007Date of Patent: March 16, 2010Assignee: Janssen Pharmaceutica NVInventors: Ellen Codd, Scott L. Dax, Michele Jetter, Mark McDonnell, James J. McNally, Mark Youngman
-
Patent number: 7674828Abstract: The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.Type: GrantFiled: May 8, 2008Date of Patent: March 9, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Hannguang J. Chao, Huji Tuerdi, Timothy F. Herpin, Jacques Y. Roberge, Yalei Liu, Michael R. Lawrence, Robert P. Rehfuss, Charles G. Clark, Jennifer X. Qiao, Timur Gungor, Patrick Y. S. Lam, Tammy C. Wang, Rejean Ruel, Alexandre L'Heureux, Carl Thibeault, Gilles Bouthillier, Dora M. Schnur
-
Patent number: 7662222Abstract: This invention relates to the use of a combination of selected substances in paint to prevent the settlement and growth of different biofouling organisms with a reduced negative effect on the ecosystems compared to present methods.Type: GrantFiled: June 23, 2009Date of Patent: February 16, 2010Assignee: I-Tech ABInventors: Magnus Nydén, Camilla Fant
-
Publication number: 20100028348Abstract: The present invention is directed to methods of modulating the activity of an isoform of manganese superoxide dismutase which is useful for the treatment of diseases such as heart failure.Type: ApplicationFiled: September 17, 2009Publication date: February 4, 2010Applicant: MITOTEK, LLCInventor: Paul Q. Anziano
-
Patent number: 7655677Abstract: The present invention provides a composition for controlling a house insect pest, such as termites, ants or cockroaches, which comprises, as active ingredients, at least two compounds selected from the group consisting of (a) a certain pyridine compound, (b) a benzoylurea compound, (c) a pyrethroid compound and (d) a certain hydrazone compound; and a composition for controlling a house insect pest, which comprises, as an active ingredient, a certain hydrazone compound.Type: GrantFiled: April 18, 2008Date of Patent: February 2, 2010Assignee: Ishihara Sangyo Kaisha, Ltd.Inventors: Masayuki Morita, Osamu Imai
-
Publication number: 20090324580Abstract: The present invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for treatment of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria.Type: ApplicationFiled: March 9, 2007Publication date: December 31, 2009Applicants: CENIX BIOSCIENCE GMBH, INSTITUTO DE MEDICINA MOLECULAR , FACULDADE DE MEDICINA DA UNIVERSIDADA DE LISBOAInventors: Michael Hannus, Cecilie Martin, Maria M. Mota, Miguel Prudencio, Christina Dias Rodrigues
-
Publication number: 20090306077Abstract: The present invention relates to a study on the synthesis of a novel N-(2-aminophenyl)benzamide derivative having an urea structure and represented by the general formula (1); and the utilization of a pharmacological effect of the derivative. A compound represented by the general formula (1) or a salt thereof has an effect of cellular morphological change on trabecular meshwork cells and is effective in the prevention and/or treatment of a disease considered to be related to intraocular pressure. In the formula, R1 and R2 represent a hydrogen atom, a lower alkyl group, or the like; R3 represents a hydroxy group, a lower alkoxy group, a lower cycloalkyloxy group, an aryloxy group, or the like; R4 and R5 represent a halogen atom, a lower alkyl group, a hydroxy group, a lower alkoxy group, or the like; X represents a lower alkylene group or the like; Y represents a single bond, a lower alkylene group, or the like; l and m represent 0, 1, 2, or the like.Type: ApplicationFiled: December 26, 2007Publication date: December 10, 2009Inventors: Hiroyuki Mogi, Hisashi Tajima, Noriko Mishina, Yusuke Yamazaki, Shinji Yoneda, Katsuhiko Watanabe, Junko Fujikawa, Minoru Yamamoto
-
Patent number: 7628979Abstract: Termite bait matrix containing cellulose, calco oil blue V (solvent blue 58 or 9,10-anthracenedione, 1,4-bis[(2-ethylhexyl)amino]), and optionally a termite toxicant (e.g., chitin synthesis inhibitor). Methods of monitoring termite activity in a region involving placing a termite bait matrix in the region and assessing the presence of termites at the site of the termite matrix, the termite bait matrix contains cellulose and 9,10-anthracenedione, 1,4-bis[(2-ethylhexyl)amino]. Methods of killing termites, involving placing a termite bait matrix in a termite habitat and allowing termites to feed on the bait matrix, the termite bait matrix contains cellulose, 9,10-anthracenedione, 1,4-bis[(2-ethylhexyl)amino], and a termite toxicant (e.g., chitin synthesis inhibitor).Type: GrantFiled: April 20, 2005Date of Patent: December 8, 2009Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Juan A. Morales-Ramos, Maria G. Rojas
-
Publication number: 20090280073Abstract: The invention relates to a method of enhancing/providing deposition of benefit agents using substantially surfactant free gel compositions comprising these hydrophobic and hydrophilic benefit agents. The method provides or enhances benefits associated with the benefit agents.Type: ApplicationFiled: May 6, 2008Publication date: November 12, 2009Applicant: CONOPCO, INC., D/B/A UNILEVERInventors: Rajesh Patel, Evan Charles Murphy, Rosa Mercedes Paredes
-
Patent number: 7601870Abstract: The present invention relates to aniline derivatives of the general formula I or salts thereof, described therein, and their use.Type: GrantFiled: December 20, 2005Date of Patent: October 13, 2009Assignee: H. Lundbeck A/SInventors: Christian Wenzel Tornøe, Mario Rottländer, Daniel Rodriguez Greve, Nikolay Khanzhin, Andreas Ritzén, William Patrick Watson
-
Publication number: 20090239841Abstract: Compounds of Formula I are provided. In which the variables are as described herein. Such compounds may be used to modulate CB1 activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CB1 modulation in humans, domesticated companion animals and livestock animals, including appetite disorders, obesity and addictive disorders. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies and various in vitro assays.Type: ApplicationFiled: October 24, 2005Publication date: September 24, 2009Inventors: Alan J. Hutchison, Jun Yuan
-
Publication number: 20090192192Abstract: The present invention relates to the use of compounds as broad spectrum inhibitors of bacterial biofilm formation. In particular the invention refers to a family of compounds that block the quorum sensing system of Gram-negative and Gram-positive bacteria, a process for their manufacture, pharmaceutical compositions containing them and to their use for the treatment and prevention of bacterial damages and diseases, in particular for diseases where there is an advantage in inhibiting quorum sensing regulated phenotypes of pathogens.Type: ApplicationFiled: December 17, 2008Publication date: July 30, 2009Inventors: Aldo Ammendola, Tanja Wieber, Andreas Wuzik, Martin Lang
-
Patent number: 7560591Abstract: Compounds which can be represented by the general formula (I) indicated below: and in which: A is selected independently from the carboxamide group, the thiocarboxamide group, and the carbonyl group, R1 is selected from an alkyl group having from 1 to 3 carbon atoms and the amino group, unsubstituted or substituted with the nitro group or the methyl group, R2 is selected independently from hydrogen, an alkyl group having from 1 to 4 carbon atoms, the methoxy, ethoxy, propoxy group, a mono-, bi- or tricyclic cycloalkane residue having from 5 to 12 carbon atoms, the adamantyl group, an aryl, naphthyl or heterocyclic group, unsubstituted or substituted with methyl, methoxy, hydroxy, amino or halogen groups, R3 and R4 are selected independently from hydrogen and an alkyl group having from 1 to 3 carbon atoms, R5 represents one or two substituents independently selected from hydrogen and the methyl, methoxyl and hydroxyl groups, n is a whole number from 0 to 6, and the amidine group is in the para or meta pType: GrantFiled: April 30, 2008Date of Patent: July 14, 2009Assignee: Rotta Research Laboratorium S.p.A.Inventors: Francesco Makovec, Simona Zanzola, Roberto Artusi, Lucio Claudio Rovati
-
Publication number: 20090163543Abstract: One aspect of the invention relates to HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided. The invention also provides methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.Type: ApplicationFiled: December 19, 2008Publication date: June 25, 2009Applicant: Georgetown UniversityInventors: Alan P. Kozikowski, Bin Chen
-
Publication number: 20090149510Abstract: The invention relates to compounds and methods for modulating one or more components of a kinase cascade.Type: ApplicationFiled: July 7, 2008Publication date: June 11, 2009Inventor: David G. Hangauer, JR.
-
Patent number: 7544716Abstract: This invention relates to tetrahydro-naphthalene derivatives of formula (I) in which the variable groups are as defined in the specification and claims, and tautomeric and stereoisomeric forms and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent activity as VR1 antagonists and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD. The compounds, pharmaceutical compositions containing them, and methods of treatment using them are disclosed and claimed.Type: GrantFiled: November 28, 2003Date of Patent: June 9, 2009Assignee: Xention LimitedInventors: Masaomi Tajimi, Toshio Kokubo, Masahiro Shiroo, Yasuhiro Tsukimi, Takeshi Yura, Klaus Urbahns, Noriyuki Yamamoto, Muneto Mogi, Hiroshi Fujishima, Tsutomu Masuda, Nagahiro Yoshida, Toshiya Moriwaki
-
Publication number: 20090143423Abstract: A solid dispersion product comprising at least one N-aryl urea-based pharmaceutically active agent or an agent of related structural type is obtained by a) preparing a liquid mixture containing the at least one active agent, at least one pharmaceutically acceptable matrix-forming agent, at least one pharmaceutically acceptable surfactant and at least one solvent, and b) removing the solvent(s) from the liquid mixture to obtain the solid dispersion product.Type: ApplicationFiled: October 17, 2008Publication date: June 4, 2009Applicant: ABBOTT GMBH & CO. KGInventors: Rudolf Schroeder, Tanja Heitermann
-
Publication number: 20090124686Abstract: The invention relates to urea derivatives of formula (I) as inhibitors of glycogen synthase kinase 3?, GSK-3, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which GSK-3 is involved, such as Alzheimer's disease or non-insulin dependent diabetes mellitus.Type: ApplicationFiled: July 28, 2006Publication date: May 14, 2009Applicant: NEUROPHARMA, S.A.Inventors: Ana Martinez Gil, Miguel Medina Padilla, Mercedes Alonso Cascon, Ana Fuertes Huerta, Maria Luisa Navarro Rico, Maria Jose Perez Puerto, Ana Castro Morera, Ester Martin Aparicio
-
Publication number: 20090082423Abstract: Disclosed are amide, thioamide, urea and thiourea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, and diabetic-related diseases.Type: ApplicationFiled: September 10, 2008Publication date: March 26, 2009Inventors: Sampath-Kumar Anandan, Richard D. Gless, JR.
-
Patent number: 7482487Abstract: The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.Type: GrantFiled: March 10, 2005Date of Patent: January 27, 2009Assignee: Pfizer IncInventors: Alan Daniel Brown, Justin Stephen Bryans, Paul Alan Glossop, Charlotte Alice Louise Lane, Simmon John Mantell
-
Publication number: 20090023731Abstract: Disclosed are urea and thiourea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, and diabetic-related diseases.Type: ApplicationFiled: March 21, 2008Publication date: January 22, 2009Inventors: Richard D. Gless, JR., Sampath Kumar Anandan
-
Publication number: 20090023813Abstract: The invention relates to novel specifically trifluoromethyl and halogen substituted 1,3-diphenyl ureas and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects like the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as anti-infectives.Type: ApplicationFiled: December 8, 2006Publication date: January 22, 2009Applicant: Arpida AGInventors: Ralf Loewe, Sergio Lociuro, Stephen Hawser, Laurent Schmitt
-
Publication number: 20090005452Abstract: The invention relates to novel specifically trifluoromethyl and halogen substituted 1,3-diphenyl ureas and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects like the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as anti-infectives.Type: ApplicationFiled: December 8, 2006Publication date: January 1, 2009Applicant: ARIPIDA AGInventors: Ralf Loewe, Sergio Lociuro, Stephen Hawser, Laurent Schmitt
-
Publication number: 20080255239Abstract: Therapeutic compounds, and methods, compositions, and medicaments related thereto are disclosed herein.Type: ApplicationFiled: March 28, 2008Publication date: October 16, 2008Inventors: Ken Chow, Wenkui K. Fang, Evelyn G. Corpuz, Daniel W. Gil, Michael E. Garst
-
Publication number: 20080220003Abstract: The present invention is related to a compound, preferably a C5a receptor antagonist, having the following structure, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21 and R22 are individually and independently selected from the group comprising H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, alkoxyl, substituted alkoxyl, aryloxy, substituted aryloxy, arylalkyloxy, substituted arylalkyloxy, acyloxy, substituted acyloxy, halogen, hydroxyl, nitro, cyano, acyl, substituted acyl, mercapto, alkylthio, substituted alkylthio, amino, substituted amino, alkylamino, substituted alkylamino, bisalkyl amino, substituted bisalkyl amino, cyclic amino, substituted cyclic amino, carbamoyl (—CONH2), substituted carbamoyl, carboxylType: ApplicationFiled: May 30, 2006Publication date: September 11, 2008Applicant: Jerini AGInventors: Karsten Schnatbaum, Dirk Scharn, Elsa Locardi, Thomas Polakowski, Uwe Richter, Ulrich Reineke, Gerd Hummel
-
Publication number: 20080207622Abstract: Disclosed are sulfone compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, pulmonary, and diabetes-related diseases.Type: ApplicationFiled: September 28, 2007Publication date: August 28, 2008Inventor: Richard D. Gless
-
Publication number: 20080207621Abstract: Disclosed are sulfonamide compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, pulmonary, and diabetes-related diseases.Type: ApplicationFiled: September 28, 2007Publication date: August 28, 2008Inventor: Richard D. Gless
-
Publication number: 20080194633Abstract: Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.Type: ApplicationFiled: August 1, 2007Publication date: August 14, 2008Inventors: Xiangping Qian, Pu-Ping Lu, Chihyuan (Grace) Chuang, Bradley P. Morgan, David J. Morgans
-
Publication number: 20080146548Abstract: This disclosure relates to amides, aryl sulphonamides, aryl ureas, and ?,?-diketones derivatives useful as carboxylesterase esterase inhibitors. The disclosure is also directed to the use of these compounds as selective human intestinal carboxylesterase inhibitors and insect carboxylesterase inhibitors. The disclosure is also directed to pharmaceutical compositions and pesticide formulations containing these compounds, and to methods for treating or ameliorating the toxic effects following administration of drugs such as cancer therapy drugs, treating or ameliorating the effects of a drug overdose, and to the use of the compounds for increasing the effectiveness of insecticides and pesticides.Type: ApplicationFiled: February 15, 2008Publication date: June 19, 2008Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITALInventors: Philip M. Potter, Janice L. Hyatt, Christopher L. Morton, Paul P. Beroza, Komath V. Damoradan
-
Publication number: 20080125424Abstract: The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders related to the function of the calcium sensing receptor. The invention also relates to processes for making such compounds and to intermediates useful in these processes.Type: ApplicationFiled: July 10, 2007Publication date: May 29, 2008Inventors: Pierre DePrez, Sarah E. Lively, Taoues Temal
-
Publication number: 20080096943Abstract: Compounds of formula I in free or salt form, wherein T, X, R1, R2, Ra, R3, R4, R5 and U have the meanings as indicated in the specification, are useful for treating a condition mediated by CCR-3, particularly an inflammatory or allergic condition such as an inflammatory or obstructive airways disease. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.Type: ApplicationFiled: August 9, 2005Publication date: April 24, 2008Inventors: Gurdip Bhalay, Andrew Dunstan, Angela Glen, Trevor John Howe, Clive McCarthy
-
Publication number: 20080025973Abstract: Antagonists of S1P3 (Edg-3) receptors are provided for attenuation of Smad signaling in a method of down-regulation of receptor signaling and downstream decreased production of connective tissue growth factor in ocular disorders involving CTGF accumulation. Ocular disorders involving inappropriate CTGF accumulation include ocular hypertension, glaucoma, glaucomatous retinopathy, optic neuropathy, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and ocular wound healing, for example. Such disorders are treated by administering antagonists of the present invention.Type: ApplicationFiled: July 25, 2007Publication date: January 31, 2008Applicant: ALCON MANUFACTURING, LTD.Inventors: Debra L. FLEENOR, Allan R. SHEPARD, Iok-Hou PANG
-
Patent number: 7307071Abstract: Materials and methods for treating certain cancers are described, preferably cancers that result from the up-regulation of the RAF-MEK-ERK pathway, and more preferably chronic myelogenous leukemia, and which cancer is preferably resistant to the inhibition of the Bcr-Abl tyrosine kinase, imatinib.Type: GrantFiled: December 3, 2002Date of Patent: December 11, 2007Assignee: Onyx Pharmaceuticals, IncInventors: John F. Lyons, Gideon Bollag
-
Patent number: 7262220Abstract: The invention relates to urea- and urethane-substituted acylureas and to their physiologically tolerated salts and physiologically functional derivatives. In particular, the invention relates to the compounds of the formula I wherein the radicals have meanings described herein, and to their physiologically tolerated salts and to processes for their preparation. The compounds are suitable for example as antidiabetics.Type: GrantFiled: July 11, 2003Date of Patent: August 28, 2007Assignee: Sanofi-Aventis Deutschland GmbHInventors: Elisabeth Defossa, Dieter Kadereit, Thomas Klabunde, Hans-Joerg Burger, Andreas Herling, Karl-Ulrich Wendt, Erich Von Roedern, Karl Schoenafinger
-
Patent number: 7241923Abstract: The present invention relates to certain phenalkyloxy-phenyl derivatives of formula (I) and analogs, to a process for preparing such compounds, having the utility in clinical conditions associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.Type: GrantFiled: May 30, 2003Date of Patent: July 10, 2007Assignee: Astrazeneca ABInventors: Jonas Fagerhad, Lanna Li, Lindstedt Alstermark Eva-Lotte
-
Patent number: 7230133Abstract: The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.Type: GrantFiled: April 29, 2004Date of Patent: June 12, 2007Assignee: Bristol-Myers Squibb CompanyInventor: Percy Carter
-
Patent number: 7208528Abstract: Novel inhibitors of polyamine transport having inhibition constants two orders of magnitude lower than those of known compounds are disclosed. These polyamine analogues are useful pharmaceutical agents for treating diseases where it is desired to inhibit polyamine transport or other polyamine binding proteins, for example cancer and post-angioplasty injury. Novel chemical synthetic methods to obtain polyamine analogues are disclosed, including the production of a combinational polyamine library. These approaches yield analogues with desirable activities both for diagnostic and research assays and therapy. The assays of the invention are useful for high throughput screening of targets in the discovery of drugs that interact with the polyamine system.Type: GrantFiled: September 15, 1999Date of Patent: April 24, 2007Assignee: MediQuest Therapeutics, Inc.Inventors: Nicolaas M. J. Vermeulin, Christine L. O'Day, Heather K. Webb, Mark R. Burns, Donald E. Bergstrom
-
Patent number: RE39866Abstract: Modulation of the activity of the insulin receptor, enhancement of glucose uptake by cells, and other effects significant in the control and management of diabetes are accomplished using compounds of the formula wherein each A is independently a proton-accepting substituent; each R is independently a noninterfering substituent; n is 0, 1, or 2; and each linker is independently an isostere of —NHCONH— or of —N?N— or of —NHCO—. Compounds in the genus of Formula (1) can also be used for structure activity studies to identify features responsible for the relevant activities.Type: GrantFiled: June 23, 2005Date of Patent: October 2, 2007Assignee: Telik, Inc.Inventors: Richard Sportsman, Hugo O. Villar, Lawrence M Kauvar, Wayne R Spevak